Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives $37.56 Consensus Target Price from Brokerages

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has been given a consensus rating of “Moderate Buy” by the nineteen analysts that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, eleven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $37.56.

A number of brokerages recently weighed in on NTLA. Oppenheimer cut their price target on shares of Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating on the stock in a report on Monday, January 13th. Morgan Stanley lowered shares of Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $56.00 to $11.00 in a research note on Monday, January 27th. Chardan Capital dropped their price objective on Intellia Therapeutics from $91.00 to $68.00 and set a “buy” rating on the stock in a research note on Friday, February 28th. The Goldman Sachs Group reissued a “sell” rating and set a $9.00 price objective on shares of Intellia Therapeutics in a report on Friday, February 28th. Finally, HC Wainwright assumed coverage on Intellia Therapeutics in a research note on Wednesday, March 5th. They issued a “buy” rating and a $30.00 target price on the stock.

Intellia Therapeutics Trading Up 3.4 %

Shares of NTLA opened at $9.00 on Friday. The stock has a 50 day moving average of $10.09 and a 200 day moving average of $14.13. Intellia Therapeutics has a 12 month low of $8.30 and a 12 month high of $28.23. The company has a market capitalization of $931.65 million, a price-to-earnings ratio of -1.65 and a beta of 1.97.

Insiders Place Their Bets

In other news, CEO John M. Leonard sold 26,807 shares of the company’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $326,509.26. Following the transaction, the chief executive officer now owns 941,115 shares of the company’s stock, valued at approximately $11,462,780.70. This represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold 29,000 shares of company stock worth $352,551 in the last three months. 3.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Intellia Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NTLA. Regeneron Pharmaceuticals Inc. bought a new stake in shares of Intellia Therapeutics during the 4th quarter valued at about $43,177,000. Voloridge Investment Management LLC lifted its position in Intellia Therapeutics by 226.8% during the fourth quarter. Voloridge Investment Management LLC now owns 1,526,994 shares of the company’s stock valued at $17,805,000 after purchasing an additional 1,059,751 shares during the last quarter. Contrarius Group Holdings Ltd purchased a new position in Intellia Therapeutics in the 4th quarter worth approximately $11,798,000. Two Sigma Advisers LP raised its position in shares of Intellia Therapeutics by 94.5% during the 4th quarter. Two Sigma Advisers LP now owns 1,998,317 shares of the company’s stock valued at $23,300,000 after buying an additional 970,700 shares in the last quarter. Finally, Two Sigma Investments LP grew its position in Intellia Therapeutics by 88.1% in the fourth quarter. Two Sigma Investments LP now owns 1,843,743 shares of the company’s stock worth $21,498,000 after acquiring an additional 863,363 shares in the last quarter. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.